Imiquimod-d7

Imiquimod-d7 (R 837-d7) is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].

Product Specifications

Product Name Alternative

R 837-d7

UNSPSC

12352005

Target

Autophagy; HSV; Isotope-Labeled Compounds; SARS-CoV; Toll-like Receptor (TLR)

Related Pathways

Anti-infection; Autophagy; Immunology/Inflammation; Others

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection; Inflammation/Immunology

Smiles

NC1=NC2=C(C3=C1N=CN3CC([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])C=CC=C2

Molecular Formula

C14H9D7N4

Molecular Weight

247.35

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858.|[3]Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6 (6) :554-60.|[4]Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86 (19) :10338-46.|[5]Michael P Schön, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126 (6) :1338-47.|[6]Leslie van der Fits, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009, 182, 9.|[7]Ajla Smajlović, et al. Molecular and histopathological profiling of imiquimod induced dermatosis in Swiss Wistar rats: contribution to the rat model for novel anti-psoriasis treatments. Mol Biol Rep. 2021, 48, 5.|[8]Sangseo Kim, et al. Development and Optimization of Imiquimod-Loaded Nanostructured Lipid Carriers Using a Hybrid Design of Experiments Approach. Int J Nanomedicine. 2023.